产品
编 号：F544106
分子式：C15H14N4O
分子量：266.3
分子式：C15H14N4O
分子量：266.3
产品类型
规格
价格
是否有货
结构图
CAS No: 98326-32-0
产品详情
生物活性：
Senazodan (MCI 154) is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
体内研究：
Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE).Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably.Animal Model:Wistar rats (200~250 g)
Dosage:0.1~2.0 mg/kg
Administration:Left femoral vein catheterization infusion
Result:Decreased the pressor effect of norepinephrine (NE).
Animal Model:Rabbits
Dosage:0.1 mg/kg
Administration:I.v.
Result:LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
体外研究：
Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhances Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III. Senazodan (0.1 nM~0.1 mM) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca2+ is shifted to the right as compared with Ang II-alone group.
Senazodan (MCI 154) is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
体内研究：
Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE).Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably.Animal Model:Wistar rats (200~250 g)
Dosage:0.1~2.0 mg/kg
Administration:Left femoral vein catheterization infusion
Result:Decreased the pressor effect of norepinephrine (NE).
Animal Model:Rabbits
Dosage:0.1 mg/kg
Administration:I.v.
Result:LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
体外研究：
Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhances Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III. Senazodan (0.1 nM~0.1 mM) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca2+ is shifted to the right as compared with Ang II-alone group.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备